Earnings

Aldeyra Narrows Third-Quarter Loss After R&D Cut

The Tip Desk · November 11, 2026 · 3 min read

The biotech posted a $3.8 million net loss for the three months ended September 30, 2026, as research and development spending fell to $1.8 million.

Aldeyra Therapeutics (ALDX), a biotechnology company developing therapies for immune-mediated diseases, reported a net loss of $3.8 million for the three months ended September 30, 2026, down from $5.5 million in the prior quarter.

The company said the narrower loss tracked a further drop in research and development spending as it shifted from clinical work toward regulatory activity on programs including reproxalap. Research and development expenses were $1.8 million, compared with $3.5 million in the three months ended June 30, 2026.

The sequential decline followed a 67.5% year-over-year drop in the first quarter of 2026. The company attributed the latest decrease to lower external clinical development costs, personnel costs, drug product manufacturing, preclinical work and consulting.

Loss from operations was $4.1 million. General and administrative expenses were $2.3 million, down 10.6% year over year. The company said the year-over-year G&A decline was primarily driven by lower personnel costs, partly offset by higher legal and consulting costs.

Late-stage product candidates accounted for about 30% of third-quarter research and development spend, up from about 20% in the second quarter, with that late-stage spend primarily attributable to reproxalap.

The company announced the suspension of the ADX-2191 retinitis pigmentosa clinical development program and said ADX-248 has completed Phase 1 and is now Phase 2-ready.

On reproxalap, Aldeyra said that on March 17, 2026, following re-submission of the Reproxalap NDA, it received a 2026 Complete Response Letter from the FDA. After Type A and Type D meetings, it submitted a formal dispute resolution request to the FDA’s Office of New Drugs on October 26, 2026, and expects to meet with OND during the fourth quarter of 2026. Additional pipeline guidance will be provided pending resolution of the FDRR.

AbbVie had still not exercised its exclusive option as of November 5, 2026. Under the option agreement, if AbbVie exercises, it would pay a $100.0 million upfront cash payment, less prior option payments, with eligibility for up to approximately $300.0 million in regulatory and commercial milestones. The exercise period is restricted to ten business days after any FDA approval of the NDA for reproxalap in dry eye disease.

Interest expense was $438 thousand in the quarter. The company repaid the $15.0 million Hercules Capital loan on April 1, 2026 and reported no debt obligations as of September 30, 2026. Interest income was $373,748. Total other income, net, was $373,310.

Cash and cash equivalents were $41.0 million at September 30, 2026, down from $45.1 million at June 30, 2026. Stockholders’ equity was approximately $35.2 million. No shares were sold under the 2024 Jefferies sales agreement, which provides for aggregate sales proceeds of up to $75.0 million. The company said it will need to raise additional capital to fund development and that it does not expect reproxalap or other candidates to be commercially available, if at all, before further discussions with the FDA, including as part of the FDRR process.